Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives

Gerardo Cazzato 1,*†, Anna Colagrande 1,†, Valeria Andriola 2, Teresa Lettini 1,†, Sebastiano Cicco 3,†, Pragnell Mary Victoria Candance 1, Leonardo Resta 1,†, Leonardo Vincenti 2 and Giuseppe Ingravallo 1,†,†

Abstract: Background: Chronic inflammatory bowel diseases (IBDs) are gaining increasing attention, both because they can severely reduce the quantity and quality of life, and because the advent of monoclonal antibodies has profoundly changed the natural history of these diseases. In recent years, the concept of mucosal healing has assumed a certain importance, and there are more and more clinical and pharmacological trials that consider this parameter among their endpoints, so much so that it may soon be included among the desirable clinical outcomes of patients with IBD. Methods: We performed a literature review of the Pubmed, Medline, and Web of Science (WoS) databases. Results: We selected 88 articles and then removed 6 duplicates; the final sample after accurate application of the inclusion criteria numbered 73 articles, with a level of evidence rating of three or four, according to Oxfords Evidence-based medicine. Our aim was to study the histological impact of monoclonal antibody therapies on mucosal healing, taking into consideration the few studies present in the literature. To perform this review, we compared studies that examined patients with Crohn’s disease (CD) and/or ulcerative colitis (UC) undergoing monoclonal therapy versus patients undergoing other non-biological therapies (PICO statements). Conclusions: We try to delineate how monoclonal antibodies have changed the natural history of IBD, acting at the microscopic level, and we believe that a careful analysis of the histopathology and the definition of the objective criteria for “Mucosa Healing” should enable this concept to be included among the clinical endpoints of patients affected by IBD, thus contributing to a better therapeutic management of these patients.

Keywords: IBD; biological; infliximab; adalimumab; vedolizumab; histology

1. Introduction

Crohn’s disease (CD) and ulcerative colitis (UC) are the two main forms of chronic inflammatory bowel disease (IBD), an idiopathic condition characterized by a chronic fluctuating course, in which quiescent phases of variable duration are interrupted by episodes of exacerbation [1]. Although the tendency towards a different distribution of the lesions and specific clinicopathological stigmata generally allows for a differentiation between CD and UC, in about 10–15% of cases, it is not yet possible to make a clear distinction between the two conditions [1,2]. In such cases, the term “indeterminate colitis” is used: obviously, the correct diagnostic classification of IBD cannot ignore a prior exclusion of causes of non-inflammatory colitis [3–5]. IBDs are more frequent in
industrialized countries (Northern Europe and North America), where incidence rates have begun to stabilize after a phase of progressive increase in the last 50 years [6,7]: CD is estimated at 5–6/100,000 people/year, with a prevalence of 27–105 cases/100,000, while CU is estimated at around 6–15 cases/100,000 people/year, with a prevalence of 80–150 cases/100,000 [1,6]. Conversely, incidence and prevalence rates continue to rise in low incidence areas (Southern Europe, Asia, and developing countries) [1,7].

From a microscopic standpoint, in CD erosions, fissurations and deep ulcers are observed with a transmural pattern, and the variable presence of neutrophil granulocytes, eosinophils, lymphocytes and plasma cells with a “discontinuous” pattern, as well as epithelioid and giant cell granulomas, can be seen in about 50% of cases, mainly located in the submucosa [5,6]. Instead, in UC, there is a primary involvement of the mucosa and, in the most active cases, of the submucosa. The most characteristic lesion is the formation of crypt abscesses of neutrophils which, by inducing necrosis of the crypt epithelium, generate true ulcers [7,8].

Despite the medical attention given to IBD and the considerable efforts made in researching the underlying causes, it is still not clear and fully understood what the risk factor responsible for this pathology is [1,5–7]. Therefore, the concept of “risk factors” linked to CD/UC, of which genetics are a part, is used, as there is evidence of, and redeeming of, genes that make a person more prone to developing Crohn’s disease than the general population. In addition, people who have a close relative (e.g., parent, brother/sister, or child) with Crohn’s disease or UC are at a higher risk of developing these conditions [6]. An abnormal reaction of the immune system to the bacteria in the intestine has been proposed, capable of creating intestinal dysbiosis and a greater chance of developing IBD. Among the environmental factors, viruses, bacteria, diet, smoking, stress, and some drugs have been studied and analyzed [1,7,8]. Furthermore, from epidemiological studies, it would seem that living in urban areas (cities) or in the more developed countries of the Northern Hemisphere, as well as belonging to the Caucasian race, may constitute an additional factor of vulnerability [1]. Finally, age plays a significant role: IBD is more likely to occur for the first time between the ages of 10 and 40, although it can begin at any age [6–8].

The primary therapeutic goals in a patient with CD and/or UC are to induce remission and maintenance (for as long as possible) of the quiescent state, as well as to manage the onset of any complications such as erythema nodosum, gangrenous pyoderma, migrating polyarthritis, ocular lesions, liver and biliary tract lesions, ankylosing spondylitis, or sacroiliitis [1,8,9]. The first-line inductive therapy in patients with CD/UC in the clinical mild–moderate activity phase is 5-aminosalicylic acid or Mesalazine, although molecules such as Budenoside (CD) or Prednisone and their equivalents (mostly UC) are also commonly used [10]. A valid alternative is the use of immunosuppressive drugs, such as Tioguanine derivatives (azathioprine, 6-mercaptopurine) or methotrexate and cyclosporine [8,10]. In addition to these “therapeutic weapons”, patients can now also be prescribed new biological drugs, or the so-called monoclonal antibodies, such as infliximab and adalimumab (chimeric-human and completely humanized anti-TNFalpha, respectively) or vedolimumab (anti-integrin-alfa4-beta7 expressed on the surface of a particular leukocytte subtype) [10,11]. In more detail, infliximab binds TNFalpha, an inflammatory cytokine produced by monocytes, macrophages and T lymphocytes, adhering to the membranes of Th1 lymphocytes, and is able to determine cell lysis through an antibody-dependent and/or cell-mediated toxin [10,12]. Therefore, this molecule is able to lead to the depletion of specific populations of subepithelial inflammatory cells, improving the clinical picture of IBD [12]. On the other hand, adalimumab [12–17] is able to bind with high affinity to TNF-alpha and to prevent the interaction of this inflammatory cytokine with its own receptors (p55 and p75). In addition to neutralizing the TNF-alpha present in the systemic circulation, this monoclonal antibody is able to bind the TNF-alpha expressed on the cell surface of monocytes, inducing apoptosis and lysis of these cells in the presence of complement. Finally, vedolizumab is a monoclonal anti-integrin α4β7 antibody, with selective action on intestinal lymphocyte traffic, and therefore has an innovative mecha-
nism of action, which is based on the selective inhibition of lymphocytes that transit and are recruited into the inflamed intestine. The drug, in fact, by binding specifically to the integrin α4β7, a protein expressed in a particular subgroup of circulating white blood cells, inhibits the binding of this protein to the adhesion molecule cellular (MAdCAM-1), overexpressed in blood vessels and lymph nodes of the gastrointestinal tract inflamed. By inhibiting this bond, the drug prevents the passage of lymphocytes from the blood circulation to the intestinal wall, the site of chronic inflammation at the base of UC and MC [18–23].

In recent times, the concept of “mucosal healing” (MH) has been arising, increasing interest both because of its clinical importance and its histopathological features [9,12]. In fact, there are two types of MH: endoscopic and histological. Although there has not yet been an unambiguous definition by the authors, we tend to define endoscopic MH as “the complete absence of all inflammatory and ulcerative lesions in all segments of the intestine at endoscopy”. This definition is quite limiting [24], and does not take into due consideration the various stages of disease severity.

Even the definition of histological MH has not yet been universally defined: the contemporary idea is to consider the absence of neutrophil granulocytes as a sign of histological mucosal healing, but there are various discrepancies in the literature regarding a precise description of this entity [18,24,25]. For these reasons, histological remission in UC and/or CD is not currently considered a clinical goal, probably also due to the complexity and/or subjectivity of application of the best known histological scores (Geboes [15], Nancy [16], Robarts), except in the research and pharmacological trials fields [12]. It is also well recognized that histological MH often does not correspond to endoscopic MH, which is why a patient can potentially still present histological IBD damage even in the absence of endoscopic signs [26]. Precisely for this reason, it is essential to acquire biopsies of the gastrointestinal tract even in the presence of endoscopic MH, as the choice of the most appropriate therapeutic treatment strictly depends on the outcome of the histological evaluation.

The advent of monoclonal antibodies (Infliximab, Adalimumab, Certolizumab, and Vedolizumab [18,23,24]) has had a strong clinical impact on primary endpoints, such as the induction and maintenance of clinical disease remission for both CD and UC [1,2,6–9,24], but also on inducing endoscopic and histological mucosal healing (MH) [24–26].

From this standpoint, the concept and definition of “mucosal healing” has a great importance in clinical practice, because recent evidence shows that MH is associated with long-term symptomatic remission and a longer relapse-free interval [27], as well as a reduction in the frequency of hospitalizations, complications and surgical resections [28], [29,30] and a significant improvement in the quality of life [31]. Additionally, MH is associated with a reduction in cancer risk and cancer-related mortality [24]. Although MH has classically been defined as the absence of ulcers “or” an improvement in endoscopic scores, such as the symptom-based Crohn’s Disease Activity Index (CDAI), Crohn’s Disease Severity Endoscopic Index (CDEIS), and/or Crohn’s Disease Simplified Endoscopic Activity Score (SES-CD) and others, all this does not faithfully depict the extent and course of the disease. Hence, an objective study of MH by histology may offer a much more adequate and effective clinical-pathological management [31,32].

In this paper, we report the main histopathological alterations in IBD described in the literature of IBD patients induced by monoclonal Ab therapy.

2. Materials and Methods

A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A search of PubMed, Medline, and Web of Science (WoS) databases was made for the period 2010–2021, inserting the terms Crohn’s disease and ulcerative colitis in combination with each of the following: Biological drugs; Histopathology; Mucosa healing. Only articles in English were selected. The last search was run on 26 July 2021. Eligible articles were assessed according to the Oxford
Centre for Evidence-Based Medicine 2011 guidelines [20]. Review articles, meta-analyses, observational studies, letters to the editor, and comments to the letters were all included. Other potentially relevant articles were identified by manually checking the references in the included literature.

An independent extraction of the articles was performed by two investigators according to the inclusion criteria. Disagreement was resolved by discussion between the two review authors. Since the study designs, participants, treatment measures, and reported outcomes varied markedly, we focused on describing the histopathological findings, their relation to the clinical severity of the disease, use of biological drugs, and other relevant investigations. The review was performed according to the PICO statements, the characteristics of which are summarized in Table 1.

Table 1. PICO statements utilized in this review.

| PICO Facets | Considerations |
|-------------|----------------|
| Patient (P) | Persons with histological diagnosis of IBD (CD e/o UC) |
| Intervention (I) | Therapy with monoclonal antibody |
| Comparison (C) | Therapy without monoclonal antibody |
| Outcome (O) | Histological difference in remission induced by Ab-monoclonal therapy compared to other therapies |

The limitations of a literature review of this nature is the complete reliance on previously published research and the availability of these studies using PRISMA guidelines.

3. Results

A total of 88 records were initially identified in the literature search, of which six were duplicates. After screening for eligibility and inclusion criteria, 73 publications were ultimately included (Figure 1). Major study and clinical characteristics are summarized in 2. The majority of publications were reviews (n = 44), followed by observational prospective studies (n = 21) and comments to letters (n = 8). All studies included were rated as level 4 or 5 evidence for clinical research as detailed in the Oxford Centre for Evidence-Based Medicine 2011 guidelines [20]. Table 2 summarizes the main studies used in the realization of this review.

Table 2. Main studies used in the realization of this review.

| Number of Reference | Author(s) | Year(s) | Type of Paper | Therapeutic Treatment | Endpoint of MH (Y/N) | Modification of MH |
|---------------------|-----------|---------|---------------|-----------------------|---------------------|--------------------|
| [1]                 | Baumgart et al. | 2007    | Review        | Not applicable        | Not applicable      | Not applicable     |
| [2]                 | Sairenji et al. | 2017    | Review        | Not applicable        | Not applicable      | Not applicable     |
| [9]                 | Boal Carvalho et al. | 2017 | Review        | Not applicable        | Not applicable      | Not applicable     |
| [18]                | Arijs et al. | 2018    | Clinical Trial| Vedolizumab          | Yes                 | 55% responders     |
| [19]                | Dai et al.   | 2014    | Clinical Trial| Infliximab           | No                  | Not applicable     |
| [28]                | Fiorino et al.| 2011    | Review        | Not applicable        | Not applicable      | Not applicable     |
| [33]                | Neurath et al.| 2012    | Review        | Not applicable        | No                  | Not applicable     |
| [34]                | Ferrante et al.| 2012  | Review        | Monoclonal Ab        | Yes                 | Yes                |
| [35]                | Rogler et al. | 2012    | Review        | Monoclonal Ab        | Yes                 | Yes                |
| [36]                | Seidelin et al.| 2013   | Review        | Monoclonal Ab        | Yes                 | Yes                |
| Number | Reference | Author(s) | Year(s) | Type of Paper | Therapeutic Treatment | Endpoint of MH (Y/N) | Modification of MH |
|--------|-----------|-----------|---------|---------------|----------------------|---------------------|--------------------|
| 37     | [37]      | Osterman  | 2013    | Review        | Various therapy      | Yes                 | Not applicable     |
| 38     | [38]      | Dulai et al. | 2015 | Review        | Monoclonal Ab       | No, but desirable   | Not applicable     |
| 39     | [39]      | Florholmen | 2015    | Review        | Monoclonal Ab Infliximab (only CD) | Yes | Not applicable |
| 40     | [40]      | Yu et al.  | 2015    | Original article | Infliximab, Ustekinumab (only CD) | No, but desirable | Not applicable     |
| 41     | [41]      | Shah et al. | 2016  | Review with meta-analysis | Adalimumab Vedolizumab | Yes | Yes |
| 42     | [42]      | Vickers et al. | 2016 | Review        | Monoclonal Ab (only UC) | Yes | Not applicable |
| 43     | [43]      | Reimink et al. | 2016  | Review        | Various therapies Monoclonal Ab (only UC) | Yes | Not applicable |
| 44     | [44]      | Eder et al.  | 2016   | Original article | Monoclonal Ab | No | Not applicable |
| 45     | [45]      | Cholapranee et al. | 2017 | Review        | Monoclonal Ab | Yes | Yes |
| 46     | [46]      | Kurashima et al. | 2017 | Review | Various therapies Monoclonal Ab and others oral therapies | Not applicable | Not applicable |
| 47     | [47]      | Pantavou et al. | 2019 | Meta-analysis | Monoclonal Ab and Tofacinib (only UC) | Yes | Yes |
| 48     | [48]      | Singh et al.  | 2018   | Review        | Various therapies Monoclonal Ab (only UC) | Yes | Yes |
| 49     | [49]      | Leppkes et al. | 2018 | Editorial | Monoclonal Ab and others oral therapies | No | Not applicable |
| 50     | [50]      | Antonelli et al. | 2018 | Review | Monoclonal Ab and others oral therapies | Yes | Not applicable |
| 51     | [51]      | Castiglione et al. | 2019 | Original article | Monoclonal Ab (only UC) | No | Not applicable |
| 52     | [52]      | Park et al.  | 2019    | Original article | Monoclonal Ab | No | Not applicable |
| 53     | [53]      | Samaan et al. | 2019 | Review | Monoclonal Ab | Yes, deep histological remission | Yes |
| 21     | [54]      | Pigneur et al. | 2019 | Randomized controlled trial | Monoclonal Ab (only childrens with CD) | Yes | Yes |
| 54     | [54]      | Löwenberg et al. | 2019 | Original article | Vedolizumab (only CD) | Yes | Yes, 64% of patients |
| 22     | [22]      | Li K et al.  | 2019    | Clinical trial | Ustekinumab (only CD) | Yes | Yes |
| 23     | [55]      | Pouillon et al. | 2019 | Review | Vedolizumab (only UC) | Yes | Yes |
| 56     | [56]      | Cucchiara et al. | 2020 | Review | Monoclonal Ab | Yes | Not applicable |
| 23     | [23]      | Nardone et al. | 2020 | Review | Monoclonal Ab | Yes | Not applicable |
| 57     | [57]      | Petryszyn et al. | 2020 | Review | Monoclonal Ab | Yes | Yes |
| 58     | [58]      | Kucharzik et al. | 2020 | Review Comparative study | Monoclonal Ab | Not applicable | Not applicable |
| 59     | [59]      | Sagani et al.  | 2020    | Review | Monoclonal Ab | Yes | Not applicable |
| 60     | [60]      | Li et al.  | 2020    | Review | Ustekinumab (only UC) | Yes | Not applicable |
4. Discussion

The histopathological definition of MH must take into account the various conditions that can influence the clinical picture: first of all, the accumulation of neutrophils in the
intestinal lumen, parallel to ulcerations of the mucosa and the symptoms of IBD, with a more or less marked aggression of the glands, appear to be the “primum movens”, as they are in other districts of the gastrointestinal tract, such as the stomach [38–43,61–63]. Transepithelial migration of neutrophils is regulated by CD44v6 and CD55, as well as ICAM-1 (intercellular adhesion molecule-1) on epithelial cells, and has been associated with epithelial damage [44] Table 3.

Table 3. Main features of CD versus UC. It should be noted that, in about 25–30% of cases, it is not easy to discriminate between the two diseases.

| Clinical Findings | Histological Findings |
|-------------------|------------------------|
| Crohn disease (CD) | Perianal lesion common; frank bleeding less frequent than in UC | Transmural discontinuous inflammation with fissuring, submucosal involvement, granuloma (25–28%), pseudopiloric metaplasia, globet cell preservation |
| Ulcerative colitis (UC) | Bloody diarrhea | Acute and chronic diffuse inflammatory infiltrate, depletion of globet cells, crypt abscesses, lymphoid aggregates, distorsion of crypts, basal plasmacytosis |

Moreover, the presence of basal plasma cells has a high predictive value for the first diagnosis of IBD and is considered an important marker, especially in the differential diagnosis with other forms of colitis. As early as 1983, Scott et al. [64] demonstrated that plasma cells were increased in rectal samples from subjects with IBD compared with controls; later, Seldenrijk et al. [65] also showed that more than 50% of patients with IBD showed basal plasmacytosis compared to controls, suggesting that this parameter could be of some importance. However, successful studies have clearly shown that the inflammatory characteristics of IBD are not constant over time; for example, a prospective study showed that focal basal plasmacytosis was found in 40% of IBD patients with symptoms for <2 weeks but disappeared after 1 year of follow-up in half of those without recurrence [61]. Therefore, the “presence of plasmacells” criterion may have a dual significance, as the presence of basal plasma cells even in various phases of the disease is a sign of pre-existing IBD. In addition, eosinophils, like plasma cells, are present with variable frequencies in all phases of the disease, both in active and quiescent colitis, as recently demonstrated. Therefore, it is impossible to consider either of these cell types as an indicator of disease activity [33–37,45,46,64–66].

Therefore, it is correct to state that the assessment of the degree of disease activity cannot disregard the recognition, topographical description, and possible presence in the glandular (crypt abscess) of neutrophilic granulocytes, and that expressions such as “IBD in the quiescent phase” of mild/moderate disease activity may actually increase the diagnostic confusion that revolves around the concept of mucosal healing [21,23,47–60,67–73].

Despite greater attention to the concepts of endoscopic and histological healing, in most of the studies available in the literature, the assessment of the histological activity of the disease was not considered a treatment endpoint. Furthermore, the endpoints for histological remission of the disease for each patient have not been defined, therefore data on this topic are still relatively scarce.

However, D’Haens et al. [71], in a multicentre, randomized, double-blind, placebo-controlled study including 30 patients with active CD, demonstrated that patients treated with intravenous infliximab at a dose of 5, 10, or 20 mg/kg improved their endoscopic scores compared to the placebo group and, moreover, they had recieved histological healing compared to the control group, albeit with a persistence of cytoarchitectonic alterations. Baert et al. partially confirmed the ability of biologics to modify the natural history of IBD: in their study, they compared 15 patients with CD refractory to first-line therapy who were treated with intravenous infliximab with 5 placebo patients. After one month of therapy, the group of patients treated showed clear signs of histological mucosal healing, with a reduction mainly in intraglandular neutrophilic granulocytes and in the lamina propria, as
well as a reduction, ascertained by immunohistochemical techniques, in CD4 +, CD8 + T lymphocytes and CD68 + macrophages [72].

Regarding the histological healing of UC patients, few studies have tried to investigate the histological changes during therapy with monoclonal antibodies [73,74]. Hassan et al. [75] studied nine patients with moderate to severe UC, treated with infliximab at a dose of 5 mg/kg, whose colon biopsies were obtained at time 0 and after 10 weeks of treatment. The activity of disease was evaluated by histological scoring, histomorphometry, and immunostaining with anti-TNF-alpha antibodies. Of the nine patients studied, six responded to therapy with a marked reduction in neutrophils, crypt abscesses, inflammatory infiltration in the lamina propria, and immunostaining for TNFalpha; three non-responding patients had no histological, clinical, and endoscopic improvement. Finally, Fratila and Craciun confirmed these data, also using electron microscopy [76].

Recently Biancone et al. [77] demonstrated the results of using Ustekinumab in UC patients, establishing a secondary endpoint of histo-endoscopic mucosal healing, in which histo-endoscopic mucosal healing was defined as achieving both endoscopic improvement (Mayo endoscopic score of 0 or 1), and histological improvement (infiltration of neutrophils in <5% of the crypts, no destruction of the crypts, and no erosion, ulceration, or granulation tissue). This contribution further emphasizes the importance of histological healing in the correct evaluation of the efficacy of monoclonal Ab.

Regarding new biological drugs, in a recent paper by Arijs et al. [18], the authors have shown that Vedolizumab (VDZ) induces histological healing in >50% of patients with endoscopic healing, with a maximum effect at week 52. VDZ also restored, although incompletely, the colonic expression of many immune-related genes in UC patients who achieved endoscopic healing at week 52. However, persistent histological and genetic dysregulations remained even in healing patients, suggesting that maintenance therapy will be needed to control intestinal inflammation. On other hand, other new molecules are increasingly entering into initial clinical use, as reported by Schmitt et al. [68]. Cobitolimod may be a new therapeutic approach in UC, as it suppresses Th17 cells and induces anti-inflammatory IL10 + macrophages and regulatory T cells, thus modifying the balance of dysregulated intestinal cytokines through an agonist-type action relative to Toll-like receptor 9. Table 4.

Table 4. Main histological features in MH described in monoclonal antibodies therapy in IBD.

| Crohn Disease | Clinical MH Features | Histological MH Features |
|---------------|----------------------|--------------------------|
| Infliximab    | Reduction of Crohn Disease index of severity (CDEIS) and simple endoscopic score for Crohn disease (SES-CD) | Reduction of inflammatory infiltrate at normal levels. Persistence of crypt architecture. |
| Adalimumab    | Reduction of Crohn’s disease activity index (PCDAI) and simple endoscopic score for Crohn disease (SES-CD) | Reduction of inflammatory infiltrate at normal levels. Reduction of epithelial damage. |
| Vedolizumab   | Reduction of Crohn Disease index of severity (CDEIS) and simple endoscopic score for Crohn disease (SES-CD) | Reduction of inflammatory infiltrate with reduction of neutrophils. Persistence of crypt architecture. |
| Ustekinumab   | Reduction of simple endoscopic score for Crohn disease (SES-CD) | Reduction of global histology activity scores (GHASs). |
Table 4. Cont.

| Crohn Disease | Clinical MH Features | Histological MH Features |
|---------------|----------------------|--------------------------|
| Ulcerative Colitis | Reduction of Mayo Endoscopic Score (MES) | Reduction of alterations of the intestinal epithelium, such as depletion of microvilli, crushing of epithelial junctions, cytoplasmic vacuolization. Restoration of the function of intracellular organelles. Reduction of pycnotic nuclei. Restoration of muciparous goblet cells with regular mucus formation and secretion. |
| Infliximab | | Restricting the inflammatory infiltrate and T-cell proliferation within the lamina propria. Downregulation of the expression of metalloproteinases and proinflammatory molecules. Restore the protective capabilities of the mucosa by reinforcing intestinal permeability and mucosal secretion, activating fibroblasts, and maintaining epithelial regeneration. |
| Adalimumab Golimumab | Reduction of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) | Limits both B- and T-cell lymphocyte fixation on the intestinal vascular endothelial cells and consequent migration to the lamina propria and tissue cells. |
| Vedolizumab | Ulcerative Colitis Endoscopic Index of Severity (UCEIS) | |

From the analysis of all the papers examined for this review, it seems correct to state that it is only relatively recently that controlled and randomized studies relating to histopathological modifications from monoclonal antibody therapy have begun to be carried out. In particular, it would seem that there are “common” effects on mucosal healing with regard to Infliximab, Adalimumab, and Vedolizumab, both in CD and in UC (reduction of inflammatory infiltrate in the chorion, restoration of the mucus-secreting capacity of the colon glands, restoration of the functions of the intestinal barrier), but also more specific effects of the molecule in question (for example, Vedolizumab, which acts selectively on B and T lymphocytes, downregulating their mucosal involvement). Moreover, from the review of the literature, it emerges clearly that anti-TNFalpha monoclonal antibodies induce a histological healing of the mucous membranes superior to previously developed therapies through two main mechanisms of action represented by the induction of apoptosis of T cells in the chorion and going to “reprogram” the effector functions of monocytes/macrophages in the direction of the M2 line, making them able to mediate a real mucosal histological healing [78].

5. Conclusions

A correct methodological approach to the evaluation of colon biopsies, in addition to the availability of comprehensive clinical and endoscopic data, are essential. In this sense, an adequate and correctly oriented number of biopsies is of fundamental importance, as highlighted in an ECCO ESP 1 statement: “For a reliable diagnosis of inflammatory bowel disease, it is necessary to perform ileo-colonoscopy rather than rectoscopy. At least two biopsies to be performed. at least five sites along the colon, including the rectum, and the terminal ileum should be performed, biopsies which should be, possibly oriented correctly, on cellulose acetate filters: ECCO Statements 4A and 4B.”.
Histologically, the presence or absence of neutrophils must be considered as the distinctive sign of differentiation between the active and the quiescent phase of the disease, and an expression of the efficacy of therapy (histological healing of the mucosa).

To reach a greater inter-observer agreement among different pathologists, it is necessary to avoid any form of morphological score in the evaluation of the colon mucosa, because, as has been amply demonstrated, these are currently all extremely complicated and subjective.

We therefore believe that, in the near future, “histological mucosal healing” should be considered as a target for therapy in IBD and as an important remission endpoint to be achieved, together with clinical, laboratory, and endoscopic signs of improvement.

**Author Contributions:** Conceptualization, G.C., A.C., S.C. and G.I.; methodology, G.C.; software, G.C.; validation, G.C., L.V. and V.A.; formal analysis, A.C.; investigation, G.C.; resources, L.V.; data curation, L.R.; writing—original draft preparation, G.C.; writing—review and editing, G.C.; visualization, T.L.; supervision, P.M.V.C. and G.I. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient to publish this paper.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Baumgart, D.C.; Carding, S.R. Inflammatory bowel disease: Cause and immunobiology. *Lancet* 2007, 369, 1627–1640. [CrossRef]  
2. Sairenji, T.; Collins, K.L.; Evans, D.V. An Update on Inflammatory Bowel Disease. *Prim. Care* 2017, 44, 673–692. [CrossRef]  
3. Mitchell, P.J.; Rabau, M.Y.; Haboubi, N.Y. Indeterminate colitis. *Tech. Coloproctol.* 2007, 11, 91–96. [CrossRef]  
4. Park, T.; Cave, D.; Marshall, C. Microscopic colitis: A review of etiology, treatment and refractory disease. *World J. Gastroenterol.* 2015, 21, 8804–8810. [CrossRef]  
5. Kaplan, G.G. The global burden of IBD: From 2015 to 2025. *Nat. Rev. Gastroenterol. Hepatol.* 2015, 12, 720–727. [CrossRef]  
6. Feakins, R.M. Ulcerative colitis or Crohn’s disease? Pitfalls and problems. *Histopathology* 2014, 64, 317–335. [CrossRef]  
7. Gajendran, M.; Loganathan, P.; Jimenez, G.; Catinella, A.P.; Ng, N.; Umapathy, C.; Ziade, N.; Hashash, J.G. A comprehensive review and update on ulcerative colitis. *Dis. Mon.* 2019, 65, 100851. [CrossRef]  
8. Feuerstein, J.D.; Moss, A.C.; Farraye, F.A. Ulcerative Colitis. *Mayo Clin. Proc.* 2019, 94, 1357–1373. [CrossRef]  
9. Boal Carvalho, P.; Cotter, J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. *Drugs* 2017, 77, 159–173. [CrossRef]  
10. Shepherd, N.A.; Warren, B.F.; Williams, G.T.; Greenson, J.K.; Lauwers, G.Y.; Novelli, M.R. (Eds.) *Morson and Dawson’s Gastrointestinal Pathology*, 5th ed.; Wiley: Hoboken, NJ, USA, 2012.

11. WHO Classification of Tumours Editorial Board. *Digestive System Tumours: WHO Classification of Tumours*; WHO: Geneva, Switzerland, 2019; Volume 1.

12. Ko, J.K.; Auyeung, K.K. Inflammatory bowel disease: Etiology, pathogenesis and current therapy. *Curr. Pharm Des.* 2014, 20, 1082–1096. [CrossRef]  
13. Koelink, P.J.; Bloemendaal, F.M.; Li, B.; Westera, L.; Vogels, E.W.M.; van Roest, M.; Gloudemans, A.K.; van ‘t Wout, A.B.; Korf, H.; Vermeire, S.; et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. *Gut* 2020, 69, 1053–1063. [CrossRef] [PubMed]  
14. Mao, R.; Hu, P.J. The Future of IBD Therapy: Where Are We and Where Should We Go Next? *Dig. Dis.* 2016, 34, 175–179. [CrossRef]  
15. Geboes, K.; Riddell, R.; Öst, A.; Jensfelt, B.; Persson, T.; Lööfberg, R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. *Gut* 2000, 47, 404–409. [CrossRef]  
16. Marchal-Bressenot, A.; Salleron, J.; Boulaqnon-Rombi, C.; Bastien, C.; Cahn, V.; Cadiot, G.; Diebold, M.D.; Danese, S.; Reinisch, W.; Schreiber, S.; et al. Development and validation of the Nancy histological index for UC. *Gut* 2017, 66, 43–49. [CrossRef]  
17. Khanna, R.; Ma, C.; Jairath, V.; Vande Casteele, N.; Zou, G.; Feagan, B.G. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. *Clin. Gastroenterol. Hepatol.* 2020. [CrossRef]  
18. Arijs, I.; De Hertogh, G.; Lemmens, B.; Van Lommel, L.; de Bruyn, M.; Vanhove, W.; Cleynin, I.; Machiels, K.; Ferrante, M.; Schuit, F.; et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. *Gut* 2018, 67, 43–52. [CrossRef]
19. Dai, C.; Liu, W.X.; Jiang, M.; Sun, M.J. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS ONE 2014, 9, e110797. [CrossRef]

20. Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. Available online: http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf (accessed on 26 July 2021).

21. Pigneur, B.; Lepage, P.; Mondot, S.; Schnitz, J.; Goulet, O.; Dore, J.; Ruemmele, F.M. Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapy-A Randomised Prospective Clinical Trial in Children With Crohn’s Disease. J. Crohns Colitis. 2019, 13, 846–855. [CrossRef]

22. Li, K.; Friedman, J.R.; Chan, D.; Pollack, P.; Yang, F.; Jacobstein, D.; Brodmerek, C.; Gasink, C.; Feagan, B.G.; Sandborn, W.J.; et al. Effects of Ustekinumab on Histologic Disease Activity in Patients with Crohn’s Disease. Gastroenterology 2019, 157, 1019.e7–1031.e7. [CrossRef]

23. Nardone, O.M.; Shivaji, U.N.; Ferruzza, V.; Ghosh, S.; Iacucci, M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm. Bowel Dis. 2020, 26, 961–969. [CrossRef]

24. Mazzuoli, S.; Guglielmi, F.W.; Antonelli, E.; Salemme, M.; Bassotti, G.; Villanacci, V. Definition and evaluation of mucosal healing in clinical practice. Dig. Liver Dis. 2013, 45, 969–977. [CrossRef]

25. Leung, C.M.; Tang, W.; Kyaw, M.; Niamul, G.; Aniwan, S.; Limsrivilai, J.; Wang, Y.F.; Ouyang, Q.; Simidibrata, M.; Abdul-lah, M; et al. Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia. J. Crohns Colitis 2017, 11, 1440–1448. [CrossRef] [PubMed]

26. Sitaram, R.; Peppercorn, M.A.; Antonioli, D.A.; Niles, J.L.; Shah, S.; Bousvaros, A.; Ransil, B.; Wild, G.; Cohen, A.; Edwards, M.D.D.; et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120, 13–20. [CrossRef] [PubMed]

27. Af Björkesten, C.G.; Nieminen, U.; Turunen, U.; Arkkila, P.E.; Sipponen, T.; Färkkilä, M.A. Endoscopic monitoring of infliximab therapy in Crohn disease: A European multicenter trial. Gastroenterology 1999, 116, 1029–1034. [CrossRef]

28. Fiorino, G.; Cesarini, M.; Indriolo, A.; Malesci, A. Mucosal healing in ulcerative colitis: Where do we stand? Curr. Drug Targets 2011, 12, 1417–1423. [CrossRef] [PubMed]

29. Dave, M.; Loftus, E.V. Mucosal healing in inflammatory bowel disease—a true paradigm of success? Gastroenterol. Hepatol. 2012, 8, 29–38.

30. D’haens, G.; Van Deventer, S.; Van Hogezand, R.; Chalmers, D.; Kothe, C.; Baert, F.; Braakman, T.; Schaible, T.; Geboes, K.; et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 2009, 137, 287–297. [CrossRef] [PubMed]

31. Schnitzer, F.; Fidder, H.; Ferrante, M.; Noman, M.; Arijs, I.; Van Assche, G.; Hoffman, I.; Van Steen, K.; Vermeire, S.; Rutgeerts, P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel Dis. 2009, 15, 1295–1301. [CrossRef] [PubMed]

32. Florholmen, J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease: Pathophysiology and pharmacology. Adv. Clin. Chem. 2013, 59, 101–123.

33. Neurath, M.F.; Travis, S.P. Mucosal healing in inflammatory bowel diseases: A systematic review. Gut 2012, 61, 1619–1635. [CrossRef]

34. Rifas, K.F.; Jahnsson, J.; Moum, B.A.; Vatn, M.H.; IBSEN Group. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology 2007, 133, 412–422. [CrossRef]

35. Osterman, M.T. Mucosal healing in inflammatory bowel disease. J. Clin. Gastroenterol. 2013, 47, 212–221. [CrossRef]

36. Rechnitzer, P.; Levesque, B.G.; Feagan, B.G.; D’Haens, G.; Sandborn, W.J. Assessment of mucosal healing in inflammatory bowel disease: Review. Gastrointest. Endosc. 2015, 82, 246–255. [CrossRef] [PubMed]

37. Florholmen, J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand. J. Gastroenterol. 2015, 50, 43–52. [CrossRef]

38. Yu, L.; Yang, X.; Xia, L.; Zhong, J.; Ge, W.; Wu, J.; Liu, H.; Liu, F.; Liu, Z. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn’s disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediat. Inflamm. 2015, 2015, 793764. [CrossRef] [PubMed]

39. Shah, S.C.; Colombel, J.F.; Sands, B.E.; Narula, N. Systematic review with meta-analysis: Mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Inflamm. Bowel Dis. 2015, 21, 1799–1812. [CrossRef] [PubMed]
Diagnostics 2021, 11, 1570

45. Cholapranee, A.; Hazlewood, G.S.; Kaplan, G.G.; Peyrin-Biroulet, L.; Ananthakrishnan, A.N. Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. *Aliment. Pharmacol. Ther.* 2017, 45, 1291–1302. [CrossRef]

46. Kurashima, Y.; Kiyono, H. Mucosal Ecological Network of Epithelium and Immune Cells for Gut Homeostasis and Tissue Healing. *Annu. Rev. Immunol.* 2017, 35, 119–147. [CrossRef] [PubMed]

47. Pantavou, K.; Yiallourou, A.I.; Piovani, D.; Ervipidou, D.; Danese, S.; Peyrin-Biroulet, L.; Bonovas, S.; Nikolopoulou, G.K. Efficacy and safety of biological agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. *United Eur. Gastroenterol. J.* 2019, 7, 1285–1303. [CrossRef]

48. Singh, S.; Fumery, M.; Sandborn, W.J.; Murad, M.H. Systematic review with network meta-analysis: First- and second-line pharmacotherapy for moderate-severe ulcerative colitis. *Aliment. Pharmacol. Ther.* 2018, 47, 162–175. [CrossRef]

49. Leppkes, M.; Siegmund, B.; Becker, C. Editorial: Immune-Epithelial Crosstalk in Inflammatory Bowel Diseases and Mucosal Wound Healing. *Front. Immunol.* 2018, 9, 1171. [CrossRef]

50. Antonelli, E.; Villanacci, V.; Bassotti, G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. *World J. Gastroenterol.* 2018, 24, 5322–5330. [CrossRef]

51. Castiglione, F.; Imperatore, N.; Testa, A.; De Palma, G.D.; Nardone, O.M.; Pellegrini, L.; Caporaso, N.; Rispo, A. One-year clinical outcomes with biologics in Crohn’s disease: Transmural healing compared with mucosal or no healing. *Aliment. Pharmacol Ther.* 2019, 49, 1026–1039. [CrossRef]

52. Park, S.H.; Hong, M.; Lee, H.S.; Ye, B.D.; Hwang, S.W.; Jung, S.; Baek, J.; Moon, J.W.; Kim, B.M.; Oh, S.H.; et al. Association of TRAP1 with infliximab-induced mucosal healing in Crohn’s disease. *J. Gastroenterol. Hepatol.* 2019, 34, 2118–2125. [CrossRef]

53. Samaa, M.; Campbell, S.; Cunningham, G.; Tamilarasan, A.G.; Irving, P.M.; McCartney, S. Biologic therapies for Crohn’s disease: Optimising the old and maximising the new. *F1000Research* 2019, 8, 1210. [CrossRef]

54. Löwenberg, M.; Vermeire, S.; Mostafavi, N.; Hoentjen, F.; Franchimont, D.; Rispens, T.; Hindryckx, P.; de Vries, A.; van der Woude, C.J.; et al. Vedolizumab Induces Endoscopic and Histologic Remission in Patients with Crohn’s Disease. *Gastroenterology* 2019, 157, 997.e6–1006.e6. [CrossRef] [PubMed]

55. Pouillon, L.; Rousseau, H.; Busby-Venner, H.; De Carvalho Bittencourt, M.; Choukour, M.; Gauchotte, G.; Zallot, C.; Danese, S.; Baumann, C.; Peyrin-Biroulet, L. Vedolizumab Trough Levels and Maintenance Therapy in Ulcerative Colitis. *J. Crohns Colitis 2019, 13, 970–975. [CrossRef] [PubMed]

56. Cucciarella, S.; D’Arcangelo, G.; Isoldi, S.; Aloi, M.; Stronati, L. Mucosal healing in Crohn’s disease: New insights. *Expert Rev. Gastroenterol. Hepatol.* 2020, 14, 335–345. [CrossRef] [PubMed]

57. Petryszyn, P.; Ekk-Cierniakowski, P.; Zurakowski, G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis. *World J. Gastroenterol.* 2020, 26, 1037–1043. [CrossRef] [PubMed]

58. Kucharzik, T.; Koletzko, S.; Kannengaesser, K.; Dignass, A. Ulcerative Colitis-Diagnosis and Therapeutic Algorithms. *Dtsch. Ärztblatt Int.* 2020, 117, 564–574. [CrossRef]

59. Sagami, S.; Kobayashi, T.; Aihara, K.; Umeda, M.; Morikubo, H.; Matsubayashi, M.; Kiyohara, H.; Nakano, M.; Ohbu, M.; Hibi, T. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. *Aliment. Pharmacol Ther.* 2020, 51, 1373–1383. [CrossRef]

60. Li, K.; Marano, C.; Zhang, H.; Yang, F.; Sandborn, W.J.; Sands, B.E.; Feagan, B.G.; Rubin, D.T.; Peyrin-Biroulet, L.; Friedman, J.R.; et al. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients with Ulcerative Colitis. *Gastroenterology* 2020, 159, 2052–2064. [CrossRef] [PubMed]

61. Schumacher, G.; Kollberg, B.; Sandstedt, B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. *Scand. J. Gastroenterol.* 1994, 29, 318–332. [CrossRef]

62. Phillipson, M.; Kubes, P. The Healing Power of Neutrophils. *Trends Immunol.* 2019, 40, 635–647. [CrossRef] [PubMed]

63. Iai, M.; Ghosh, S. Mucosal Healing—How Deep Is Enough? *Dig. Dis. 2016, 34, 160–164. [CrossRef]

64. Scott, B.B.; Goodall, A.; Stephenson, P.; Jenkins, D. Rectal mucosal plasma cells in inflammatory bowel disease. *Gut* 1983, 24, 519–524. [CrossRef]

65. Seldenrijk, C.A.; Morson, B.C.; Meuwissen, S.G.; Schipper, N.W.; Lindeman, J.; Meijer, C.J. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: Diagnostic implications. *Gut* 1991, 32, 1514–1520. [CrossRef]

66. Casellas, F.; Barreiro de Acosta, M.; Iglesias, M.; Robles, V.; Nos, P.; Aguas, M.; Riestra, S.; de Francisco, R.; Papo, M.; Borruel, N. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. *Eur. J. Gastroenterol. Hepatol.* 2012, 24, 762–769. [CrossRef] [PubMed]

67. Sumagin, R.; Robin, A.Z.; Nusrat, A.; Parkos, C.A. Transmigrated neutrophils in the intestinal lumen engage ICAM-1 to regulate the epithelial barrier and neutrophil recruitment. *Mucosal Immunol.* 2014, 7, 905–915. [CrossRef]

68. Schmitt, H.; Ulmschneider, J.; Billmeier, U.; Vieth, M.; Scarozza, P.; Sonnewald, S.; Reid, S.; Attaya, I.; Rath, T.; Zundler, S.; et al. The TLR9 Agonist Cobitolimid Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. *J. Crohns Colitis 2020, 14, 508–524. [CrossRef]

69. Di Ruscio, M.; Variola, A.; Vernia, F.; Lunardi, G.; Castelli, P.; Bocus, P.; Geccherle, A. Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients’ Response to Biological Therapy and the Need for Colectomy. *Digestion* 2021, 102, 534–545. [CrossRef]
70. Castro-Dopico, T.; Fleming, A.; Dennison, T.W.; Ferdinand, J.R.; Harcourt, K.; Stewart, B.J.; Cader, Z.; Tuong, Z.K.; Jing, C.; Lok, L.S.C.; et al. GM-CSF Calibrates Macrophage Defense and Wound Healing Programs during Intestinal Infection and Inflammation. Cell Rep. 2020, 32, 107857. [CrossRef] [PubMed]

71. Danese, S.; Sandborn, W.J.; Colombel, J.F.; Vermeire, S.; Gloverm, S.C.; Rimola, J.; Siegelman, J.; Jones, S.; Bornstein, J.D.; Feagan, B.G. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn’s Disease. Gastroenterology 2019, 157, 1007–1018.e7. [CrossRef] [PubMed]

72. Baert, F.J.; D’Haens, G.R.; Peeters, M.; Hiele, M.I.; Schaible, T.F.; Shealy, D.; Geboes, K.; Rutgeerts, P.J. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999, 116, 22–28. [CrossRef]

73. Katsanos, K.H.; Papadakis, K.A. Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics. Gut Liver 2017, 11, 455–463. [CrossRef]

74. Pizarro, T.T.; Stappenbeck, T.S.; Rieder, F.; Rosen, M.J.; Colombel, J.F.; Donowitz, M.; Towne, J.; Mazmanian, S.K.; Faith, J.J.; Hodin, R.A.; et al. Challenges in IBD Research: Preclinical Human IBD Mechanisms. Inflamm. Bowel Dis. 2019, 25 (Suppl. 2), S5–S12. [CrossRef]

75. Hassan, C.; Ierardi, E.; Burattini, O.; De Francesco, V.; Zullo, A.; Stoppino, G.; Panella, C.; Morini, S. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig. Liver Dis. 2007, 39, 811–817. [CrossRef] [PubMed]

76. Fratila, O.C.; Craciun, C. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. J. Gastrointestin. Liver Dis. 2010, 19, 147–153. [PubMed]

77. Biancone, L.; Ardizzone, S.; Armuzzi, A.; Castiglione, F.; D’Incà, R.; Danese, S.; Daperno, M.; Gionchetti, P.; Rizzello, F.; Scribano, M.L.; et al. Ustekinumab for treating ulcerative colitis: An expert opinion. Expert Opin. Biol. Ther. 2020, 20, 1321–1329. [CrossRef] [PubMed]

78. Levin, A.D.; Wildenberg, M.E.; van den Brink, G.R. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J. Crohns Colitis 2016, 10, 989–997. [CrossRef]